Induction and postremission strategies in acute myeloid leukemia: State of the art and future directions Journal Article
| Authors: | Rosenblat, T. L.; Jurcic, J. G. |
| Article Title: | Induction and postremission strategies in acute myeloid leukemia: State of the art and future directions |
| Abstract: | Advances in the understanding of the molecular pathogenesis of acute myeloid leukemia have led to the identification of diagnostic and prognostic markers, resulting in further refinement of karyotype-based risk classification. This article presents strategies for induction therapy of younger adults and approaches to postremission therapy based on prognostic features. Although some older adults may benefit from intensive chemotherapy and reduced-intensity hematopoietic stem cell transplantation, development of less intensive therapies for older patients who are not candidates for these modalities is an area of active investigation. Novel molecularly targeted agents and other investigational chemotherapeutic drugs now entering late-stage development are also discussed. © 2011 Elsevier Inc. |
| Keywords: | cancer chemotherapy; cancer survival; event free survival; treatment outcome; survival rate; unclassified drug; acute granulocytic leukemia; gene mutation; leukemia, myeloid, acute; fludarabine; lenalidomide; review; treatment duration; disease free survival; cytarabine; topotecan; drug megadose; cell proliferation; interleukin 2; unindexed drug; low drug dose; multiple cycle treatment; etoposide; antineoplastic combined chemotherapy protocols; incidence; granulocyte macrophage colony stimulating factor; maintenance therapy; cytogenetics; hematopoietic stem cell transplantation; continuous infusion; high risk patient; tumor suppressor gene; mitoxantrone; daunorubicin; tipifarnib; transcription factor erg; remission induction; allogeneic hematopoietic stem cell transplantation; 5 aza 2' deoxycytidine; idarubicin; myeloblastin; flt3 ligand; granulocyte colony stimulating factor; cyclosporin; clofarabine; tioguanine; azacitidine; gemtuzumab ozogamicin; isocitrate dehydrogenase; induction; consolidation; molecular pathology; nucleophosmin; chemosensitization; histamine; molecular targeted therapy; midostaurin; acute myeloid leukemia; postremission therapy; ccaat enhancer binding protein alpha; valspodar; flurdarabine; laromustine |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 25 |
| Issue: | 6 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-12-01 |
| Start Page: | 1189 |
| End Page: | 1213 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2011.09.007 |
| PROVIDER: | scopus |
| PUBMED: | 22093583 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 9 December 2011" - "CODEN: HCNAE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work